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Abstract 
Approximately 90% of head and neck squamous cell carcinoma (HNSCC) overexpress epidermal growth 
factor receptor (EGFR). EGFR plays a role in predicting and modulating the response of HNSCC patients 
to radiation. Cetuximab is established as potent radiosensitizer.  However data regarding use of tyrosine 
kinase inhibitors like gefitinib is limited. Aim of this study is to establish the radiosensitizer efficacy of 
daily gefitinib with concurrent chemoradiotherapy in patients with locally advanced non metastatic HNSCC 
(LAHNSCC). Between July, 2008 to October, 2011, 104 patients with LAHNSCC were randomized into 
two arms; in Arm A (experimental arm), patients received gefitinib (250 mg orally daily along with 
cisplatin based chemoradiation) and Arm B (control arm), patients received concurrent cisplatin based 
chemoradiation with Cisplatin dose of 100mg/m2 intravenous infusion given on Days 1 and 22 with 
conventional fractionated radiation of 60-66 Gray. Response assessments were done using RECIST and 
adverse events by NCI-CTCAE version 3. The median follow-up time was 26 months (range 2-35 months).  
There was statistical difference in overall response between the two arms (p value 0.041) in favour of 
gefitinib arm (n=48) with overall response (ORR=CR+PR) of 91.6 % versus 69.5% in conventional 
cisplatin chemoradiation (n=46).  Disease Free Survival favored the Gefitinib arm with Log Rank p value 
of 0.008. Gefitinib arm resulted in more grade 2 and 3 dermatitis, mucositis and diarrheal events. Adding 
Gefitinib to conventional chemoradiation in treatment of LAHNSCC improves ORR and DFS, with an 
increase in incidence of manageable toxicity.  
Keywords: Chemoradiation, Gefitinib, Radiosensitizer. 
 
1. Introduction 
Locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC) have high risk of local recurrence 
and distant metastasis. Approximately 90% of HNSCC overexpress epidermal growth factor receptor 
(EGFR). Preclinical studies revealed EGFR as a predictor of radiation response of Head-neck cancer and 
have identified EGFR and its downstream signaling molecules as appealing targets for therapeutic 
intervention. Bonner showed that adding Cetuximab, an anti-EGFR antibody, to radiation yielded improved 
locoregional (LR) control and overall survival (Bonner et al. 2006). While role of cetuximab is established, 
data regarding use of Tyrosine kinase inhibitor (TKI) is limited. The aim of the study is to establish whether 
there is any benefit of adding Gefitinib to conventional chemoradiation. 
 
2. Materials and Method   
From July, 2008 to October, 2011, we enrolled patients with locally advanced, chemotherapy and radiation 
naïve non-metastatic squamous cell carcinoma of head and neck region (SCCHN) into this single 
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institution, interventional, open label, parallel, prospective, randomized controlled study that comprised of 
two cohorts: Arm A patients receiving additional gefitinib along with cisplatin based chemoradiation 
(experimental arm) and Arm B patients receiving concurrent cisplatin based chemoradiation (control arm). 
It was a simple randomization procedure by lottery in 1:1 allocation. The method of allocation 
concealment was sequentially numbered, sealed, opaque envelopes. 
Patients with histologically proven stage III or IV (A and B) SCCHN, with no metastatic evidence on 
radiological or laboratory investigations; ECOG performance status 0–1; at least 40 years of age; normal 
bone marrow, hepatic, and renal functions; no prior invasive malignancy; no prior systemic therapy for 
SCCHN and no prior radiation therapy to head and neck region were eligible for inclusion in the study.  
Patients were excluded from study if suffering with co-morbid conditions like uncontrolled diabetes, 
myocardial infarction or cerebrovascular accident in preceding one year, chronic obstructive lung disease 
or asthma that might require aborting the intervention; with nasopharyngeal cancer, as the incidence of 
cancer of this anatomic subsite is very low in the patient population attending this tertiary oncology centre; 
and with oral cavity cancers which were primarily treated with surgery followed by adjuvant radiation.  
This clinical research protocol and the described study was conducted in compliance with the Helsinki 
protocol, Good Clinical Practices standards and associated local body ethical committee regulations. 
The pretreatment work-up evaluation included history and physical examination including detailed ENT 
examination with biopsy,  panendoscopy, hematology and biochemistry profile, dental evaluation, 
nutrition status evaluation, chest x-ray and contrast enhanced computed tomography of the head and neck.  
2.1 Concurrent Chemotherapy and Targeted therapy 
Concurrent cisplatin (CDDP, cis-diethylamine dichloroplatinum) chemotherapy was administered at 100 
mg/m2 intravenously, (IV) repeated every 21 days during RT for patients in both the treatment cohorts on 
days 1 and 22.  Routine hydration with 1000 mL normal saline given before chemotherapy over 2 hours 
and 1000 mL of normal saline given over 2 hours after chemotherapy . CDDP was administered in 250 mL 
of normal saline with mannitol 12.5 g IV over 30 minutes immediately after cisplatin. Standard antiemetic 
prophylaxis consisted of 16 mg of ondansetron and 16 mg of dexamethasone given as intravenous bolus as 
pre-medication 30 minutes prior to chemotherapy. Cisplatin was given on Saturdays. Anti-emetic 
prophylaxis was continued with ondansetron and domperidone or metoclopramide orally two to three days 
after each cycle of cisplatin. Patients in arm A started taking gefitinib orally starting on day 1 of radiation, 
seven days a week till the end of chemoradiotherapy at 250 mg daily and 4 hours prior to daily radiation 
dose.   
2.2 Radiation 
Radiation was given with 1.25 MeV (average energy) photons using Cobalt 60 according to standard fields, 
including the primary tumour and involved lymph nodes. We prescribed a minimum tumour dose of 60-66 
Gy (two Gy per fraction, five fractions per week) depending on tumour size, with larger tumours receiving 
the larger dose. Thus, patients who had a primary tumour and lymph nodes with a diameter of 4 cm or less, 
or both, were given 60 Gray (Gy) while others received 66 Gy. Patients were assigned five fractions per 
week, given one fraction daily from Monday to Friday. Patients were immobilized in a supine treatment 
position in a custom-made head-and-neck thermoplastic mask manufactured in the mould room. All 
patients underwent simulation, using conventional or contrast enhanced computed tomogram (CECT) scan 
planning, with 3 mm cut sections. The radiation field encompasses the gross disease (primary tumor and/or 
nodal disease) with a 2 cm margin. Two lateral parallel opposed fields were mostly used to treat the 
primary tumor and/or upper neck with a matched anterior field, as needed for the supraclavicular region. 
Field reductions at approximately 40 to 44 Gy were suggested to exclude the spinal cord from the large 
photon fields. After a total dose of 44 Gy, only the primary tumor and clinically or radiographically 
involved nodes were treated with a margin of 1 cm. 
2.3 Response assessment 
The response assessments in the patients were evaluated 8 weeks after completion of treatment by the head 
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and neck surgeon and radiation oncologist using the RECIST criteria. All patients underwent CECT Scan 
of head and neck along with detailed ENT examination with a directed biopsy performed in patients with 
clinical and /or radiological suspicion of persistent primary and/or nodal disease. Wherever feasible, 
patients with residual disease were sent for salvage surgery for removal of primary and/or nodal disease.  
The patients with no evidence of residual primary and nodal disease were followed up every 3 months till 
the end of study to assess the toxicity and the disease free survival rates.  
The primary end point of the study was assessing the response rates by RECIST criteria (complete 
response [CR], partial response [PR], and overall response rate [ORR= CR+PR]). The secondary endpoints 
of the study were disease-free survival comparison (DFS, defined as locoregional recurrence or distant 
metastasis due to the cancer), acute toxicity (during  chemoradiotherapy, weekly toxicity assessment was 
carried out using the NCI Common Toxicity Criteria Adverse Events version 3; acute toxicity assessment 
continued for an additional 8 weeks from the last date of chemoradiotherapy). 
  
2.4 Statistical analysis 
For calculation of sample size GPower statistical software was used and for other statistical analysis SPSS 
version 17 was used. With review of literature it was estimated that the complete response (CR) rate using 
cisplatin based chemoradiation for LASCCHN was 40%. For study to be statistically significant, gefitinib 
containing arm must show at least 20% increased CR over conventional chemoradiation arm. Thus the 
absolute effect was 60%. The power of the test was kept at 80%. Assuming attrition rate of 10% after 
review of previous hospital records, additional 8 patients would be recruited for the study. Randomization 
procedure was planned with 1:1 allocation. So the minimum sample size of study was 80, with 40 patients 
in each arm. 
With Continuous data was summarized as Mean ± SE and categorical variables as frequencies. Chi Square 
and Fisher’s tests for comparison of categorical data of demographic, stage profiles, treatment response and 
toxicity profiles and for continuous variables independent t test was used for comparison. Disease free 
survival was compared using Kaplan Meier analysis with log rank test. Subset analysis of tumour response 
was planned for anatomical subsites and stage of disease presentation. All tests were 2 tailed with p value 
less than 0.05 taken to be significant. Data are presented as 3-year actuarial values.  
 
3. Results 
Between July, 2008 and October 2011, 120 patients with LASCCHN were initially enrolled for inclusion in 
the study. 16 patients were left out of study after failing the eligibility criteria. The remaining 104 patients 
were randomized for study. The accruals of all patients were completed within the stipulated 6 months after 
initiation of study.  48 patients in arm A and 46 patients in arm B were analyzed. 
The distribution of patients and tumour characteristics were similar in the two groups with baseline profiles 
(table 1). The average age in arm A (n=48) receiving concurrent chemoradiation with cisplatin and gefitinib 
was 56.6 ± 0.76 years (range 44 - 68 years), while for patients in arm B (n=46) receiving cisplatin and 
concurrent chemoradiation, the average age was 55.1 ± 1.00 years (range 42-68 years). Radiation was 
completed in within a median time of 52 days (range: 45 to 56 days).  
The response assessment was done at 8 weeks post-treatment using RECIST. The overall response rates 
(ORR=CR+PR) were statistically significant (91.6 %) in gefitinib containing arm against 69.5% for 
conventional chemoradiation (Chi-square p value ~ 0.041). (table 2). The response analysis according to 
anatomical subsites and stages showed no significant differences between the arms. The Disease Free 
Survival (DFS) using Kaplan Meier analysis favored the Gefitinib arm with Log Rank (Mantel-Cox) 7.001, 
df 1 and p value of 0.008 (significant) (table 3A and B). The median disease free survival was 23 months 
for gefitinib and concurrent chemoradiation versus 17 months for only chemoradiotherapy arm. The 
patients in Arm B, receiving additional gefitinib had higher incidence of dermatitis (overall 80% vs 66.67% 
in Arm A, p value 0.025) and diarrhea (overall 80% vs 57.14% in Arm A, p value 0.010) (table 4).  No 
patient in either of the treatment arms had Grade 4 toxicity graded according to Common Terminology 
Criteria for Adverse Events version 3.  
Journal of Biology, Agriculture and Healthcare     www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 






Over one third of all cancers in India occur in the head and neck. Nearly 60% of patients of head and neck 
cancer present with locally advanced but non metastatic disease. Squamous-cell carcinoma of the head and 
neck is predominantly a locoregional disease, and the primary treatment methods are surgery and 
Radiotherapy (Overgaard et al. 1986). 
Traditional treatment with surgery and/ or radiation produces a 5-year survival rate of 40% or less. 
Historically, disease recurrence has been seen to be predominantly locoregional, whereas distant failure rate 
is 20% to 30%. Chemotherapy has been successfully employed in different clinical settings and role of 
chemotherapy in the curative management of advanced locoregional head and neck squamous cell 
carcinoma has been established. A rationale for combining chemotherapy and radiotherapy concomitantly 
in the treatment of locally advanced head and neck cancers exists. Chemotherapy can sensitize tumors to 
radiotherapy by inhibiting tumor repopulation, preferentially killing hypoxic cells, inhibiting the repair of 
sublethal radiation damage, sterilizing micrometastatic disease outside of the radiation fields and decreasing 
the tumor mass, which leads to improved blood supply and reoxygenation.  Fractionated radiotherapy, in 
turn, may sensitize tumors to chemotherapy by inhibiting the repair of drug-induced damage and by 
decreasing the size of the tumor mass, leading to improved blood supply and enhanced drug delivery.  
Chemotherapy can be used in the setting of either (1) prior to locoregional therapy (neoadjuvant), (2) 
concurrent with definitive radiation therapy, or (3) after locoregional therapy with or without concomitant 
radiation therapy (adjuvant). In 1987, the Radiation Therapy Oncology Group (RTOG) first reported results 
from a phase II trial testing radiation and concurrent high-dose cisplatin (100 mg/m2 given every 3 weeks 
during radiation therapy). They showed a complete response rate of 71% and a 4-year survival of 34% in a 
cohort of 124 patients.  Concurrent chemoradiotherapy has become the standard nonsurgical treatment for 
locoregional advanced head and neck cancer. A lot of clinical trials have been undergone to establish the 
optimal chemotherapeutics for use concurrently with radiation to treat head and neck cancer. Results of 
cooperative group randomized trials in the United States favored use of cisplatin at a dose of 100 mg/m2 
every 3 weeks during conventional fractionation radiation. A survival advantage was demonstrated with the 
use of the above regimen over radiotherapy alone in unresectable disease and nasopharyngeal cancer 
(Al-Sarraf et al. 1998; Adelstein et al. 2003). Concurrent chemoradiotherapy with cisplatin in laryngeal 
cancer resulted in a higher rate of organ preservation. Finally, the combination of cisplatin and radiation 
therapy was superior to radiation therapy alone after a potentially curative surgical resection. A number of 
combination chemotherapy regimens, predominantly Cisplatin/fluorouracil (5-FU), have also been studied 
along with radiation and they produced superior results over radiation alone in randomized trials (Argiris 
2002). 
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In the update of Meta-analysis of chemotherapy in head and neck cancer (MACH-NC), twenty-four new 
trials, most of them of concomitant chemotherapy, were included with a total of 87 trials and 16,485 
patients. The hazard ratio of death was 0.88 (p<0.0001) with an absolute benefit of 4.5% at 5 years for 
chemotherapy, and a significant interaction (p<0.0001) between chemotherapy timing (adjuvant, induction 
or concomitant) and treatment. Both direct and indirect comparisons showed a more pronounced benefit of 
the concomitant chemotherapy as compared to induction chemotherapy. For the 50 concomitant trials, the 
hazard ratio (of death) was 0.81 (p<0.0001) and the absolute benefit of 6.5% at 5 years. There was a 
decreasing effect of chemotherapy with age (p=0.003, test for trend). The MACH-NC confirmed the benefit 
of concomitant chemotherapy and was greater than the benefit of induction chemotherapy (Pignon et al 
2009). However, sensitizing effects are not tumour specific and affect adjacent normal tissues within the 
radiation field. Concurrent chemoradiotherapy trials have consistently reported an increased incidence of 
acute grade 3 and 4 toxic effects, with mucositis and dermatitis being the most prominent. This rise creates 
concern about chronic toxic effects, including consequential late effects, which evolve from persistent 
severe acute toxic effects. Interestingly, multiple studies have confirmed that, compared with radiation 
alone, the long-term side effects of concurrent chemoradiotherapy, such as on swallowing function or 
speech, are not increased (Bernier et al. 2004; Cooper et al. 2004; Bachaud et al. 1996). 
Epidermal growth factor receptor (EGFR) is overexpressed in several epithelial malignancies, including 
head and neck squamous cell carcinoma (HNSCC). EGFR overexpression occurs in up to 90% of tumors 
with overexpression of EGFR ligands such as transforming growth factor alpha. EGFR plays a critical role 
in HNSCC growth, invasion, metastasis and angiogenesis. EGFR inhibition through anti-EGFR antibody 
therapy or small-molecule inhibitors of EGFR may act in a synergistic fashion with radiotherapy through 
inhibition of cellular proliferation, tumor angiogenesis and DNA repair. The introduction of targeted agents 
against the epidermal growth factor receptor (EGFR) pathway has improved survival in locally advanced 
squamous cell head and neck cancer (LAHNC) though as monotherapy they have yielded only modest 
clinical outcomes. 
Potential mechanisms for lack of response to EGFR inhibition in HNSCC include constitutive activation of 
signaling pathways independent of EGFR, as well as genetic aberrations causing dysregulation of the cell 
cycle. EGFR-directed therapy may be optimized by identifying and selecting those HNSCC patients most 
likely to benefit from EGFR inhibition. Resistance to EGFR inhibition may be circumvented by 
combination therapy employing EGFR inhibitors together with other treatment modalities (Kalyankrishna 
& Grandis 2006). 
Bonner et al. reported the results of the first major randomized trial in head and neck cancer that directly 
compared radiotherapy alone with radiotherapy and concurrent biologic-targeted therapy in the definitive 
treatment of patients with locally advanced or unresectable head and neck cancers (Bonner et al. 2006). In 
this trial, 424 patients with stage III or IV oropharynx, larynx or hypopharynx cancer were randomized to 
either radiotherapy alone (either 2 Gy daily to 70 Gy, 1.2 Gy twice daily to 72-76.8 Gy, or accelerated 
fractionation with concomitant boost to 72 Gy as per RTOG 90-03) or to the same radiotherapy plus 
cetuximab, an anti-EGFR antibody. Local control at 3 years favored combined modality therapy (47 vs 34%; 
p < 0.01); 3-year overall survival was superior with cetuximab and radiotherapy (55 vs 45%; p = 0.05). The 
rate of distant metastases was similar in both groups. Toxicities were similar in both groups except that 
acneiform rash and infusion reactions were more common in the combined modality group. 
Gefitinib is an anilinoquinazoline with antineoplastic activity which inhibits the catalytic activity of 
numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in 
inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of 
ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting 
in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit 
angiogenesis. Gefitinib has been shown to inhibit repair of RT-induced DNA double-strand breaks (Shintani 
et al 2003). EGFR expression levels in head and neck cancer (HNC) cell lines correlated with increased RT 
resistance (Akimoto et al. 1999) and gefitinib enhanced radiosensitivity in HNC cells. In xenograft tumor 
models, gefitinib in combination with RT resulted in synergistic growth inhibition (Ochs et al. 2004). 
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Gefitinib applied before RT and before and/or during CDDP/fluorouracil improved the cytotoxic effect in 
HNC cell lines (Magne et al. 2002). Thus, combining gefitinib with RT or chemoradiotherapy showed 
cooperative effects in preclinical studies and warranted clinical investigation in patients with LAHNC 
(Ciardiello et al. 2000 and Sirotnak et al. 2000). 
Changhu Chen et al. in a “Phase I Trial of Gefitinib in Combination With Radiation or Chemoradiation for 
Patients With Locally Advanced Squamous Cell Head and Neck Cancer”, showed that Gefitinib (250 or 
500 mg daily) was well tolerated with concomitant boost RT or concurrent chemoradiotherapy with weekly 
CDDP. Protracted administration of gefitinib for up to 2 years at 250 mg daily was also tolerated well 
(Chen et al. 2007) 
Our study has also proved the effectiveness of Gefitinib as radiosensitizer; as with addition of it, DFS is 
significantly improved. There are certain limitations of this study. First, study population is very small with 
smaller number of patients in each subgroups.  But this study, though being first of its kind, has shown 
some light regarding improved response and it should be validated with further studies accruing larger 
number of patients and more preferably in multicentric trials among different populations. Secondly, as 
most head-neck cancer recurs within two years, we kept study period within three years with median follow 
up of 26 months. So, what we achieved with improved DFS in study arm, might change over longer 
follow-up when calculating cancer free survival and overall survival. Third and most important one is that, 
this being a non-funding study and availability of EGFR-expression testing being very restricted in eastern 
part of India, patients could not be randomized based on this profile. So, the benefit what we have achieved 
from this study, is from a heterogeneous group of population, comprising both EGFR-positive and 
EGFR-negative patients. Larger study randomized with EGFR expression profile is needed to comment on 
whether Gefitinib can be used in EGFR-negative patients too or it is should be used only in EGFR-positive 
population with exact degree of response and benefit in this cohort. 
Like previous study result, this study also shows that addition of Gefitinib increases the incidence of 
dermatitis and diarrhea. Lastly this is to declare that our study was a small study, to validate the results, 
large randomized study is necessary. 
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TABLE 1A. BASELINE COMARISON BETWEEN PATIENTS INCLUDED IN BOTH THE COHORTS 
BASELINE PROFILES GROUP [no(%)] P value 
CONCURRENT 
CISPLATIN  and 
DAILY GEFITINIB 
250mg with RT (n=48) 
CONCURRENT 
CISPLATIN with RT 
(n=46) 
SEX male 42 (87.5) 40 (87) 0.937 
female 6 (12.5) 6 (13) 
AGE (in years, Mean ± SE) [median] 56.6 ± 0.76 [57.0] 55.1 ± 1.00 [56] 0.206 
ECOG PERFORMANCE 
STATUS 
ECOG 0 26 (54.2) 28 (60.9) 0.511 
ECOG 1 22 (45.8) 18 (39.1) 
HEMOGLOBIN ≥ 10gm% 27 (56.3) 33 (71.7) 0.118 
< 10 gm% 21 (43.8) 13 (28.3) 
CREATININE 
CLEARANCE 
50-60 ml/min 19 (39.6) 15 (32.6) 0.219 
61-70 ml/min 18 (37.5) 25 (54.3) 
71-80 ml/min 11 (22.9) 6 (13.1) 
 
 
TABLE 1B. BASELINE COMPARISON BETWEEN PATIENTS INCLUDED IN BOTH 
THE COHORTS 
Primary site AJCC Stage  
GROUP [no(%)]  
P value CONCURRENT 
CISPLATIN  and 
DAILY GEFITINIB 





OROPHARYNX III 3 (33.3) 5 (35.7) 
0.805 IVA 3 (33.3) 6 (42.9) 
IVB 3 (33.3) 3 (21.4) 
LARYNX III 6 (35.3) 1 (5.9) 
0.105 IVA 8 (47.1) 12 (70.6) 
IVB 3 (17.6) 4 (23.5) 
HYPOHARYNX III 9 (40.9) 8 (53.3)  
0.435 IVA 7 (31.8) 2 (13.3) 
IVB 6 (27.3) 5 (33.3) 
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FIGURE 1. Bar diagram showing the response rates among patients in the study 
 
 





CISPLATIN  and 
DAILY GEFITINIB 
250mg with RT (n=48) 
CONCURRENT 
CISPLATIN with RT 
(n=46) 
CR 34 (70.8) 22 (47.8) 
0.041* 
PR 10 (20.8) 10 (21.7) 
SD 2 (4.2) 9 (19.6) 
PD 2 (4.2) 5 (10.9) 
CR-Complete response; PR – Partial response; SD – Stable disease; PD – Progressive 
disease.  Assessment by RECIST criteria. 
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Table 2 B. PRIMARY SITE and STAGE SPECIFIC RESPONSE COMPARISON BETWEEN 
GROUPS 
 
Parameters RESPONSE GROUP (no,%)  
CONCURRENT 
CISPLATIN  and 
DAILY GEFITINIB 
250mg with RT (n=48) 
CONCURRENT 
CISPLATIN with RT 
(n=46) 
P value 
STAGE AJCC Stage III CR 17 (94.4) 11 (78.6) 0.178 
PR 1 (5.6) 3 (21.4) 
SD 0  0  
AJCC Stage IVA CR 13 (72.2) 9 (45.0) 0.099 
PR 4 (22.2) 3 (15.0) 
SD 1 (5.6) 7 (35.0) 
PD 0  1 (5.0) 
AJCC Stage IVB CR 4 (33.3) 2 (16.7) 0.620 
PR 5 (41.7) 4 (33.3) 
SD 1 (8.3) 2 (16.7) 
PD 2 (16.70 4 (33.3) 
PRIMARY SITE OROPHARYNX CR 6 (66.7) 3 (21.4) 0.176 
PR 1 (11.1) 4 (28.6) 
SD 2 (22.2) 6 (42.9) 
PD 0  1 (7.1) 
LARYNX CR 11 (64.7) 11 (64.7) 0.112 
PR 6 (35.3) 2 (11.8) 
SD 0  2 (11.8) 
PD 0  2 (11.8) 
HYPOPHARYNX CR 17 (77.3) 8 (53.3) 0.366 
PR 3 (13.6) 4 (26.7)  
SD 0  1 (6.7)  
PD 2 (9.1) 2 (13.3)  
CR-Complete response; PR – Partial response; SD – Stable disease; PD – Progressive disease.  Assessment by 
RECIST criteria. 
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Table 3A. Means for Survival Time 
Group Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
CONCURRENT CISPLATIN and  
DAILY GEFITINIB 250mg with RT (n=48) 
24.215 1.940 20.413 28.017 
CONCURRENT CISPLATIN with RT 
(n=46) 
15.924 2.591 10.847 21.002 
Overall 20.969 1.649 17.737 24.201 
 
Figure 2. Kaplan Meier Survival curve showing improved DFS 
with gefitinib containing chemoradiation arm versus conventional 
chemoradiation. 
Journal of Biology, Agriculture and Healthcare     www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 















Table 3B. DISEASE FREE SURVIVAL comparison between two treatment arms 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 7.001 1 0.008 
Table 4. TOXICITY PROFILE COMPARISON (CTCAE version 3) 
 
ADVERSE EVENTS 
GROUP [no(%)] P value 
CONCURRENT CISPLATIN  
and DAILY GEFITINIB 
250mg with RT (n=48) 
CONCURRENT 
CISPLATIN with RT 
(n=46) 
Dermatitis GRADE  1 11 (22.9) 35 (76.1) 
0.000 GRADE  2 25 (52.1) 7 (15.2) 
GRADE  3 12 (25) 4 (8.7) 
Mucositis GRADE  1 17 (35.4) 32 (69.6) 
0.000 GRADE  2 30 (62.5) 10 (32.6) 
GRADE  3 1 (2.1) 4 (8.7) 
Diarrhea GRADE  0 14 (29.2) 25 (54.3) 
0.000 
GRADE  1 5 (10.4) 15 (32.6) 
GRADE  2 21 (43.8) 6 (13.0) 
GRADE  3 8 (16.7) 0 
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